Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 1796
119th Congress(2025-2026)
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Introduced
Introduced
Introduced in House on Mar 3, 2025
Overview
Text
Introduced in House 
Mar 3, 2025
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Mar 3, 2025)
Mar 3, 2025
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 1796 (Introduced-in-House)


119th CONGRESS
1st Session
H. R. 1796


To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

IN THE HOUSE OF REPRESENTATIVES

March 3, 2025

Mr. James (for himself, Mr. Veasey, Mr. Carter of Louisiana, Mr. Davis of Illinois, and Mrs. Kiggans of Virginia) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025”.

SEC. 2. Sickle cell disease treatment prevention and treatment.

(a) In general.—Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—

(1) in paragraph (1)(A)(iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”;

(2) in paragraph (2)(D), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”;

(3) in paragraph (3)—

(A) in subparagraph (A), by striking “enter into a contract with” and inserting “make a grant to, or enter into a contract or cooperative agreement with,”; and

(B) in subparagraph (B), in each of clauses (ii) and (iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”; and

(4) in paragraph (6), by striking “$4,455,000 for each of fiscal years 2019 through 2023” and inserting “$8,205,000 for each of fiscal years 2025 through 2029”.

(b) Sense of Congress.—It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.